PDCD1 and hepatocellular carcinoma: Finally, hyperprogressive disease has been reported in 8–12.7% advance HCC patients received anti-PD-1 therapy [11, 26], but there were insufficient data to evaluate HCC hyperprogression in this study, although seven patients had rapid disease progression after the first cycle of anti-PD-1 therapy.